Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

(2017) Josef S. Smolen et al.   RHEUMATOLOGY

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

(2015) Jung-Yoon Choe et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

(2015) Tsutomu Takeuchi et al.   Modern Rheumatology

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment

(2013) Jinhyun Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Evidence Synthesis for Decision Making 4

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

(2012) J. P. T. Higgins et al.   Research Synthesis Methods

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

(2011) Susanne Schmitz et al.   ANNALS OF THE RHEUMATIC DISEASES

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

(2008) D. Aletaha et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES